Cited by 838Immunotherapy and Immune ResponsesImmune Response and InflammationCancer Immunotherapy and Biomarkers

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1

Open access

Chiba, Shigeki, Baghdadi, Muhammad, Akiba, Hisaya, Yoshiyama, Hironori, Kinoshita, Ichiro, Dosaka-Akita, Hirotoshi, Fujioka, Yoichiro, Ohba, Yusuke, Gorman, Jacob V, Colgan, John D, Hirashima, Mitsuomi, Uede, Toshimitsu, Takaoka, Akinori, Yagita, Hideo, Jinushi, Masahisa·2012·Nature Immunology

DOI 10.1038/ni.2376PMC PMC3622453

Open this paper in CoChat — free account

Abstract

The mechanisms by which tumor microenvironments modulate nucleic acid-mediated innate immunity remain unknown. Here we identify the receptor TIM-3 as key in circumventing the stimulatory effects of nucleic acids in tumor immunity. Tumor-associated dendritic cells (DCs) in mouse tumors and patients with cancer had high expression of TIM-3. DC-derived TIM-3 suppressed innate immune responses through the recognition of nucleic acids by Toll-like receptors and cytosolic sensors via a galectin-9-independent mechanism. In contrast, TIM-3 interacted with the alarmin HMGB1 to interfere with the recruitment of nucleic acids into DC endosomes and attenuated the therapeutic efficacy of DNA vaccination and chemotherapy by diminishing the immunogenicity of nucleic acids released from dying tumor cells. Our findings define a mechanism whereby tumor microenvironments suppress antitumor immunity mediated by nucleic acids.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/ni.2376

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Pattern Recognition Receptors and Inflammation
Takeuchi, O., & Akira, S. (2010) · Cell · doi:10.1016/j.cell.2010.01.022 · Cited by 8,895
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
Taking dendritic cells into medicine
Steinman, R. M., & Banchereau, J. (2007) · Nature · doi:10.1038/nature06175 · Cited by 2,162
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
Zhu, C., Anderson, A. C., Schubart, A., Xiong, H., Imitola, J., Khoury, S. J., Zheng, X. X., Strom, T. B., & Kuchroo, V. K. (2005) · Nature Immunology · doi:10.1038/ni1271 · Cited by 2,057
Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Immunosuppressive Strategies that are Mediated by Tumor Cells
Rabinovich, G. A., Gabrilovich, D. I., & Sotomayor, E. M. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,747
HMGB1 is a therapeutic target for sterile inflammation and infection
Andersson, U., & Tracey, K. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101323 · Cited by 1,437

Flagged first, then by citations

Show all 50 references

Sorted by citations

Items 201–300 of 838

TIM-3 Suppresses Anti-CD3/CD28-Induced TCR Activation and IL-2 Expression through the NFAT Signaling Pathway
Tomkowicz, B. E., Walsh, E. S., Cotty, A., Verona, R. I., Chi-Sabins, N., Kaplan, F. M., Santulli-Marotto, S., Chin, C., Mooney, J. M., Lingham, R. B., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140694 · Cited by 87
Hormonal Modulation of Dendritic Cells Differentiation, Maturation and Function: Implications for the Initiation and Progress of Systemic Autoimmunity
Mackern‐Oberti, J. P., Jara, E. L., Riedel, C. A., & Kalergis, A. M. (2016) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-016-0418-6 · Cited by 83
Dysfunction of dendritic cells in tumor microenvironment and immunotherapy
Chen, J., Duan, Y.-H., Che, J., & Zhu, J. (2024) · 癌症：英文版 · doi:10.1002/cac2.12596 · Cited by 84
Control of NK Cell Activation by Immune Checkpoint Molecules
Beldi‐Ferchiou, A., & Caillat‐Zucman, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102129 · Cited by 81
Innate Immune Cells: A Potential and Promising Cell Population for Treating Osteosarcoma
Wang, Z., Wang, Z., Li, B., Wang, S., Chen, T., & Ye, Z. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01114 · Cited by 77
The Role of HMGB1 Signaling Pathway in the Development and Progression of Hepatocellular Carcinoma: A Review
Wang, X., Xiang, L., Li, H., Chen, P., Feng, Y., Zhang, J., Yang, N., Li, F., Wang, Y., Zhang, Q., et al. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160922527 · Cited by 76
News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors
Melaiu, O., Lucarini, V., Giovannoni, R., Fruci, D., & Gemignani, F. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.001 · Cited by 76
In Situ Vaccination as a Strategy to Modulate the Immune Microenvironment of Hepatocellular Carcinoma
Lurje, I., Werner, W., Mohr, R. U., Roderburg, C., Tacke, F., & Hammerich, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.650486 · Cited by 79
TIM-3 teams up with PD-1 in cancer immunotherapy: mechanisms and perspectives
Yan, Z., Wang, C., Wu, J., Wang, J., & Ma, T. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00267-6 · Cited by 84
The Role of Tumor-Associated Myeloid Cells in Modulating Cancer Therapy
Neophytou, C. M., Pierides, C., Christodoulou, M., Costeas, P., Kyriakou, T.-C., & Papageorgis, P. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00899 · Cited by 75
Emerging Trends in Immunotherapy for Cancer
Mishra, A., Ali, A., Dutta, S., Banday, S., & Malonia, S. K. (2022) · Diseases · doi:10.3390/diseases10030060 · Cited by 79
β-Catenin mediates tumor-induced immunosuppression by inhibiting cross-priming of CD8+ T cells
Liang, X., Fu, C., Cui, W., Ober-Blöbaum, J. L., Zahner, S. P., Shrikant, P. A., Clausen, B. E., Flavell, R. A., Mellman, I., & Jiang, A. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.0613330 · Cited by 74
Functional expression of Tim-3 on blasts and clinical impact of its ligand galectin-9 in myelodysplastic syndromes
Asayama, T., Tamura, H., Ishibashi, M., Kuribayashi-Hamada, Y., Onodera-Kondo, A., Okuyama, N., Yamada, A., Shimizu, M., Moriya, K., Takahashi, H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21492 · Cited by 74
New Checkpoint Inhibitors on the Road: Targeting TIM-3 in Solid Tumors
de Morais, A. L. G., Cerdá, S. S., & Miguel, M. J. D. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01218-y · Cited by 73
Life after death: targeting high mobility group box 1 in emergent cancer therapies.
Guo, Z. S., Liu, Z., Bartlett, D. L., Tang, D., & Lotze, M. T. (2013) · Europe PMC (PubMed Central) · Cited by 72
Emerging Immunotherapy for Acute Myeloid Leukemia
Tabata, R., Chi, S., Yuda, J., & Minami, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041944 · Cited by 74
Tumor microenvironment-related dendritic cell deficiency: a target to enhance tumor immunotherapy
Zhu, S., Yang, N., Wu, J., Wang, X., Wang, W., Liu, Y.-J., & Chen, J. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104980 · Cited by 71
High-mobility group box 1 serves as an inflammation driver of cardiovascular disease
Wahid, A., Chen, W., Wang, X., & Tang, X. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111555 · Cited by 71
Inhibitory Receptors and Immune Checkpoints Regulating Natural Killer Cell Responses to Cancer
Buckle, I., & Guillerey, C. (2021) · Cancers · doi:10.3390/cancers13174263 · Cited by 74
Diversity of immune checkpoints in cancer immunotherapy
Guo, Z., Zhang, R., Yang, A., & Zheng, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1121285 · Cited by 73
Modulating Both Tumor Cell Death and Innate Immunity Is Essential for Improving Radiation Therapy Effectiveness
Wu, Q., Allouch, A., Martins, I., Brenner, C., Modjtahedi, N., Deutsch, É., & Perfettini, J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00613 · Cited by 76
Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy
Chrétien, S., Zerdes, I., Bergh, J. C. S., Matikas, A., & Foukakis, T. (2019) · Cancers · doi:10.3390/cancers11050628 · Cited by 71
Tim-3 mediates T cell trogocytosis to limit antitumor immunity
Pagliano, O., Morrison, R. M., Chauvin, J.-M., Banerjee, H., Davar, D., Ding, Q., Tanegashima, T., Gao, W., Chakka, S., Deblasio, R. N., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci152864 · Cited by 73
Myeloid cells in cancer-related inflammation
Caronni, N., Savino, B., & Bonecchi, R. (2014) · Immunobiology · doi:10.1016/j.imbio.2014.10.001 · Cited by 71
Tim-3 suppresses the killing effect of Vγ9Vδ2 T cells on colon cancer cells by reducing perforin and granzyme B expression
Li, X., Lu, H., Gu, Y., Zhang, X., Zhang, G., Shi, T., & Chen, W. (2019) · Experimental Cell Research · doi:10.1016/j.yexcr.2019.111719 · Cited by 72
TIM-3 in Leukemia; Immune Response and Beyond
Rezaei, M., Tan, J., Zeng, C., Li, Y., & Ganjalıkhani-Hakemi, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.753677 · Cited by 70
Immune checkpoint blockade in HIV
Gubser, C., Chiu, C. Y. H., Lewin, S. R., & Rasmussen, T. A. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103840 · Cited by 69
Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor
Chocarro, L., Bocanegra, A., Blanco, E., Fernández, L., Arasanz, H., Echaide, M., Garnica, M., Ramos, P., Piñeiro‐Hermida, S., Vera, R., et al. (2022) · Cells · doi:10.3390/cells11152351 · Cited by 73
Significance of TIM3 expression in cancer: From biology to the clinic
Solinas, C., Silva, P. D., Bron, D., Willard-Gallo, K. E., & Sangiolo, D. (2019) · Seminars in Oncology · doi:10.1053/j.seminoncol.2019.08.005 · Cited by 72
Detection of Immune Checkpoint Receptors – A Current Challenge in Clinical Flow Cytometry
Shibru, B., Fey, K., Fricke, S., Blaudszun, A., Fürst, F., Weise, M., Seiffert, S., Weyh, M. K., Koehl, U., Sack, U., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.694055 · Cited by 70
CAR T cell-based immunotherapy and radiation therapy: potential, promises and risks
Hovhannisyan, L., Riether, C., Aebersold, D. M., Medová, M., & Zimmer, Y. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01775-1 · Cited by 69
Promising immunotherapy targets: TIM3, LAG3, and TIGIT joined the party
Lu, C., & Tan, Y. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200773 · Cited by 72
Targeting the tumor microenvironment to enhance antitumor immune responses
der Jeught, K. V., Bialkowski, L., Daszkiewicz, L., Broos, K., Goyvaerts, C., Renmans, D., Lint, S. V., Heirman, C., Thielemans, K., & Breckpot, K. (2014) · Oncotarget · doi:10.18632/oncotarget.3204 · Cited by 70
Intralesional rose bengal in melanoma elicits tumor immunityviaactivation of dendritic cells by the release of high mobility group box 1
Liu, H., Innamarato, P., Kodumudi, K. N., Weber, A. M., Nemoto, S., Robinson, J. L., Crago, G., McCardle, T. W., Royster, E. B., Sarnaik, A. A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9247 · Cited by 67
NK Cell-Based Immunotherapy for Hematological Malignancies
Sivori, S., Meazza, R., Quintarelli, C., Carlomagno, S., Chiesa, M. D., Falco, M., Moretta, L., Locatelli, F., & Pende, D. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101702 · Cited by 68
Reverting Immune Suppression to Enhance Cancer Immunotherapy
Guerrouahen, B. S., Maccalli, C., Cugno, C., Rutella, S., & Akporiaye, E. T. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01554 · Cited by 71
Functional Role of Dendritic Cell Subsets in Cancer Progression and Clinical Implications
Prete, A. D., Sozio, F., Barbazza, I., Salvi, V., Tiberio, L., Laffranchi, M., Gismondi, A., Bosisio, D., Schioppa, T., & Sozzani, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113930 · Cited by 69
Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases
Cai, X., Zhan, H., Ye, Y., Yang, J., Zhang, M., Li, J., & Zhuang, Y. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.785153 · Cited by 66
CRISPR-Cas9–Mediated TIM3 Knockout in Human Natural Killer Cells Enhances Growth Inhibitory Effects on Human Glioma Cells
Morimoto, T., Nakazawa, T., Matsuda, R., Nishimura, F., Nakamura, M., Yamada, S., Nakagawa, I., Park, Y.-S., Tsujimura, T., & Nakase, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073489 · Cited by 66
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities
Yin, N., Li, X., Zhang, X., Xue, S., Cao, Y., Niedermann, G., Lu, Y., & Xue, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01826-z · Cited by 74
MicroRNA-466l inhibits antiviral innate immune response by targeting interferon-alpha
Li, Y., Fan, X., He, X., Sun, H., Zou, Z., Yuan, H., Xu, H., Wang, C., & Shi, X. (2012) · Cellular and Molecular Immunology · doi:10.1038/cmi.2012.35 · Cited by 66
Tim-3 protects decidual stromal cells from toll-like receptor-mediated apoptosis and inflammatory reactions and promotes Th2 bias at the maternal-fetal interface
Wang, S., Cao, C., Piao, H., Li, Y., Yu, T., Zhang, X., Zhang, D., Sun, C., Zhu, R., Wang, Y., et al. (2015) · Scientific Reports · doi:10.1038/srep09013 · Cited by 65
The complex roles of efferocytosis in cancer development, metastasis, and treatment
Tajbakhsh, A., Gheibi hayat, S. M., Movahedpour, A., Savardashtaki, A., Loveless, R., Barreto, G. E., Teng, Y., & Sahebkar, A. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111776 · Cited by 64
High Mobility Group Box 1 in Human Cancer
Rapoport, B. L., Steel, H. C., Theron, A. J., Heyman, L., Smit, T., Ramdas, Y., & Anderson, R. (2020) · Cells · doi:10.3390/cells9071664 · Cited by 68
Damage-Associated Molecular Patterns and the Systemic Immune Consequences of Severe Thermal Injury
Comish, P. B., Carlson, D., Kang, R., & Tang, D. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000439 · Cited by 66
High Mobility Group Box 1: Biological Functions and Relevance in Oxidative Stress Related Chronic Diseases
Taverna, S., Tonacci, A., Ferraro, M., Cammarata, G., Cuttitta, G., Bucchieri, S., Pace, E., & Gangemi, S. (2022) · Cells · doi:10.3390/cells11050849 · Cited by 64
Immunogenicity of necrotic cell death
Gamrekelashvili, J., Greten, T. F., & Korangy, F. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1741-x · Cited by 63
Immune checkpoints in tumor microenvironment and their relevance to the development of cancer stem cells
Khosravi, N., Mokhtarzadeh, A., Baghbanzadeh, A., Hajiasgharzadeh, K., Khaze, V., Hemmat, N., Safarzadeh, E., & Baradaran, B. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118005 · Cited by 62
Activation of Sympathetic Signaling in Macrophages Blocks Systemic Inflammation and Protects against Renal Ischemia-Reperfusion Injury
Hasegawa, S., Inoue, T., Nakamura, Y., Fukaya, D., Uni, R., Wu, C.-H., Fujii, R., Peerapanyasut, W., Taguchi, A., Kohro, T., et al. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020121723 · Cited by 62
Identification of a small-molecule Tim-3 inhibitor to potentiate T cell–mediated antitumor immunotherapy in preclinical mouse models
Ma, S., Tian, Y., Peng, J., Chen, C., Peng, X., Zhao, F., Li, Z., Li, M., Zhao, F., Sheng, X., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adg6752 · Cited by 63
Immunoregulation of Dendritic Cells by the Receptor T cell Ig and Mucin Protein-3 via Bruton’s Tyrosine Kinase and c-Src
Maurya, N., Gujar, R., Gupta, M., Yadav, V., Verma, S., & Sen, P. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400395 · Cited by 62
Discovery and Mechanistic Study of a Novel Human-Stimulator-of-Interferon-Genes Agonist
Zhang, X., Liu, B., Tang, L., Su, Q., Hwang, N., Sehgal, M., Cheng, J., Ma, J., Zhang, X., Tan, Y., et al. (2019) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00010 · Cited by 62
Targeting B7‐1 in immunotherapy
Chen, R., Ganesan, A., Okoye, I., Arutyunova, E. I., Elahi, S., Lemieux, M. J., & Barakat, K. (2019) · Medicinal Research Reviews · doi:10.1002/med.21632 · Cited by 62
Post-translational modifications of high mobility group box 1 and cancer.
Richard, S. A., Jiang, Y., Xiang, L. H., Zhou, S., Wang, J., Su, Z., & Xu, H. (2017) · PubMed Central · Cited by 62
Emerging immunotherapies for metastasis
Edwards, S. C., Hoevenaar, W. H. M., & Coffelt, S. B. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01160-5 · Cited by 62
Tim-3 promotes intestinal homeostasis in DSS colitis by inhibiting M1 polarization of macrophages
Jiang, X., Yu, J., Shi, Q., Xiao, Y., Wang, W., Chen, G., Zhao, Z. J., Wang, R., He, X., Hou, C., et al. (2015) · Clinical Immunology · doi:10.1016/j.clim.2015.07.008 · Cited by 62
Dying to Be Noticed: Epigenetic Regulation of Immunogenic Cell Death for Cancer Immunotherapy
Cruickshank, B. M., Giacomantonio, M., Marcato, P., McFarland, S. A., Pol, J. G., & Gujar, S. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00654 · Cited by 62
Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints
Hargadon, K. M. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.37 · Cited by 63
Current Landscape of Cancer Immunotherapy: Harnessing the Immune Arsenal to Overcome Immune Evasion
Mitra, A., Kumar, A., Amdare, N. P., & Pathak, R. (2024) · Biology · doi:10.3390/biology13050307 · Cited by 61
Dysregulated Tim-3 expression on natural killer cells is associated with increased Galectin-9 levels in HIV-1 infection
Jost, S., Moreno‐Nieves, U. Y., García-Beltrán, W. F., Rands, K., Reardon, J., Tóth, I., Trocha, A. K., Altfeld, M. A., & Addo, M. M. (2013) · Retrovirology · doi:10.1186/1742-4690-10-74 · Cited by 62
TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells
Kikushige, Y., & Miyamoto, T. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1433-6 · Cited by 61
Immune checkpoint inhibitors for cancer treatment
Park, J., Kwon, M., & Shin, E. (2016) · Archives of Pharmacal Research · doi:10.1007/s12272-016-0850-5 · Cited by 61
HMGB1 Protein
Ugrinova, I., & Pasheva, E. A. (2016) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2016.10.001 · Cited by 63
Multimodal Spatial Profiling Reveals Immune Suppression and Microenvironment Remodeling in Fallopian Tube Precursors to High-Grade Serous Ovarian Carcinoma
Kader, T., Lin, J., Hug, C. B., Coy, S., Chen, Y., de Bruijn, I., Shih, N. N. C., Jung, E., Pelletier, R. J., Leon, M. L., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-1366 · Cited by 62
New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials
Jin, H., Qin, S., He, J., Xiao, J., Li, Q., Mao, Y., & Zhao, L. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.70691 · Cited by 58
Targeting tumor immunosuppressive microenvironment for pancreatic cancer immunotherapy: Current research and future perspective
Li, Y., Xiang, S., Pan, W., Wang, J., Zhan, H., & Liu, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1166860 · Cited by 58
Tim-3 adapter protein Bat3 acts as an endogenous regulator of tolerogenic dendritic cell function
Tang, R., Acharya, N., Subramanian, A., Purohit, V., Tabaka, M., Hou, Y., He, D., Dixon, K. O., Lambden, C., Xia, J., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abm0631 · Cited by 59
Tim-3: Expression on immune cells and roles at the maternal-fetal interface
Hu, X., Tang, M., Mor, G., & Liao, A. (2016) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2016.10.113 · Cited by 58
Immune checkpoint blockade in pancreatic cancer: Trudging through the immune desert
Li, X., Gulati, M., Larson, A. C., Solheim, J. C., Jain, M., Sushil Kumar, K., & Batra, S. K. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.08.009 · Cited by 56
Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas
Baghdadi, M., Nagao, H., Yoshiyama, H., Akiba, H., Yagita∥, H., Dosaka‐Akita, H., & Jinushi, M. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1371-9 · Cited by 56
Self-citation
NK cell expression of Tim-3: First impressions matter
So, E. C., Khaladj-Ghom, A., Ji, Y., Amin, J., Song, Y., Burch, E. E., Zhou, H., Sun, H., Chen, S., Bentzen, S. M., et al. (2019) · Immunobiology · doi:10.1016/j.imbio.2019.03.001 · Cited by 56
The Tumor Macroenvironment
Rutkowski, M. R., Svoronos, N., Perales‐Puchalt, A., & Conejo-Garcia, J. R. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2015.04.011 · Cited by 56
Immune checkpoint inhibitors associated cardiovascular immune-related adverse events
Jo, W., Won, T., Daoud, A., & Čiháková, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1340373 · Cited by 55
One Stone, Two Birds: The Roles of Tim-3 in Acute Myeloid Leukemia
Wang, Z., Chen, J., Wang, M., Zhang, L., & Yu, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.618710 · Cited by 55
Immune checkpoints and cancer development: Therapeutic implications and future directions
Mehdizadeh, S., Bayatipoor, H., Pashangzadeh, S., Jafarpour, R., Shojaei, Z., & Motallebnezhad, M. (2021) · Pathology - Research and Practice · doi:10.1016/j.prp.2021.153485 · Cited by 55
Next generation of immune checkpoint molecules in maternal‐fetal immunity*
Zhao, S., Muyayalo, K. P., Luo, J., Huang, D., Mor, G., & Liao, A. (2022) · Immunological Reviews · doi:10.1111/imr.13073 · Cited by 54
Immune cellular components and signaling pathways in the tumor microenvironment
Yenyuwadee, S., Aliazis, K., Wang, Q., Christofides, A., Shah, R., Patsoukis, N., & Boussiotis, V. A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.08.004 · Cited by 54
Strategies to overcome DC dysregulation in the tumor microenvironment
Mestrallet, G., Sone, K., & Bhardwaj, N. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.980709 · Cited by 56
Tumor-Derived Exosomes: Hidden Players in PD-1/PD-L1 Resistance
Vautrot, V., Bentayeb, H., Causse, S., Garrido, C., & Gobbo, J. (2021) · Cancers · doi:10.3390/cancers13184537 · Cited by 55
Tim-3 and Tim-4 as the potential targets for antitumor therapy
Cheng, L., & Ruan, Z. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1056953 · Cited by 53
High resolution X-ray and NMR structural study of human T-cell immunoglobulin and mucin domain containing protein-3
Gandhi, A. K., Kim, W. M., Sun, Z.-Y. J., Huang, Y., Bonsor, D. A., Sundberg, E. J., Kondo, Y., Wagner, G., Kuchroo, V. K., Petsko, G. A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-35754-0 · Cited by 53
Cross-Presenting XCR1+ Dendritic Cells as Targets for Cancer Immunotherapy
Audsley, K. M., McDonnell, A. M., & Waithman, J. C. (2020) · Cells · doi:10.3390/cells9030565 · Cited by 54
Phosphorylation and Stabilization of PD-L1 by CK2 Suppresses Dendritic Cell Function
Zhao, X., Wei, Y., Chu, Y., Li, Y., Hsu, J.-M., Jiang, Z., Liu, C., Hsu, J. L., Chang, W., Yang, R., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-2300 · Cited by 55
Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor
Schwartz, S., Patel, N., Longmire, T. A., Jayaraman, P., Jiang, X., Lu, H., Baker, L. M., Velez, J., Ramesh, R., Wavreille, A., et al. (2022) · Immunotherapy Advances · doi:10.1093/immadv/ltac019 · Cited by 54
MicroRNA-223 Promotes Type I Interferon Production in Antiviral Innate Immunity by Targeting Forkhead Box Protein O3 (FOXO3)
Chen, L., Song, Y., Li, H., Wan, X., Lai, L., Dai, F., Liu, Y., & Wang, Q. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.700252 · Cited by 51
The costimulatory activity of Tim-3 requires Akt and MAPK signaling and its recruitment to the immune synapse
Kataoka, S., Manandhar, P., Lee, J., Workman, C. J., Banerjee, H., Szymczak-Workman, A. L., Kvorjak, M., Lohmueller, J. J., & Kane, L. (2021) · Science Signaling · doi:10.1126/scisignal.aba0717 · Cited by 52
Sonosensitizer nanoplatform-mediated sonodynamic therapy induced immunogenic cell death and tumor immune microenvironment variation
Zheng, J., Sun, Y., Long, T., Yuan, D., Yue, S., Zhang, N., & Yang, Z. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2058653 · Cited by 50
The Role of TIM-3 in Hepatocellular Carcinoma: A Promising Target for Immunotherapy?
Ganjalıkhani-Hakemi, M., Jafarinia, M., Azizi, M., Rezaeepoor, M., Isayev, O., & Bazhin, A. V. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.601661 · Cited by 53
Immune Checkpoints in Cancers: From Signaling to the Clinic
Pisibon, C., Ouertani, A., Bertolotto, C., Ballotti, R., & Chéli, Y. (2021) · Cancers · doi:10.3390/cancers13184573 · Cited by 51
Liver-primed CD8+ T cells suppress antiviral adaptive immunity through galectin-9-independent T-Cell immunoglobulin and mucin 3 engagement of high-mobility group box 1 in mice
Dolina, J. S., Braciale, T. J., & Hahn, Y. S. (2013) · Hepatology · doi:10.1002/hep.26938 · Cited by 50
Adaptive NKG2C+CD57+ Natural Killer Cell and Tim-3 Expression During Viral Infections
Kared, H., Martelli, S., Tan, S. W., Simoni, Y., Chong, M. L., Yap, S. H., Newell, E. W., Pender, S. L. F., Kamarulzaman, A., Rajasuriar, R., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00686 · Cited by 54
Exploiting NK Cell Surveillance Pathways for Cancer Therapy
Barrow, A., & Colonna, M. (2019) · Cancers · doi:10.3390/cancers11010055 · Cited by 48
The Role of Myeloid Cells in GBM Immunosuppression
Lin, Y.-J., Wu, C. Y.-J., Wu, J. Y., & Lim, M. K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.887781 · Cited by 53
Latency-Associated Protein Acr1 Impairs Dendritic Cell Maturation and Functionality: A Possible Mechanism of Immune Evasion by Mycobacterium tuberculosis
Siddiqui, K. F., Amir, M., Gurram, R. K., Khan, N., Arora, A., Rajagopal, K., & Agrewala, J. N. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit595 · Cited by 48
Checkpoint molecules coordinately restrain hyperactivated effector T cells in the tumor microenvironment
Yang, M., Du, W., Yi, L., Wu, S., He, C., Zhai, W., Yue, C., Sun, R., Menk, A. V., Delgoffe, G. M., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2019.1708064 · Cited by 49
The New Era of Cancer Immunotherapy
Khalil, D. N., Budhu, S., Gasmi, B., Zappasodi, R., Hirschhorn-Cymerman, D., Plitt, T., Henau, O. D., Zamarin, D., Holmgaard, R., Murphy, J. T., et al. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2015.04.010 · Cited by 46
Tim-3 is a Marker of Plasmacytoid Dendritic Cell Dysfunction during HIV Infection and Is Associated with the Recruitment of IRF7 and p85 into Lysosomes and with the Submembrane Displacement of TLR9
Schwartz, J. A., Clayton, K., Mujib, S., Zhang, H., Rahman, A. K. M. N.-U., Liu, J., Yue, F. Y., Benko, E., Kovacs, C. M., & Ostrowski, M. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601298 · Cited by 47
Identification and characterization of M6903, an antagonistic anti–TIM-3 monoclonal antibody
Zhang, D., Jiang, F., Zaynagetdinov, R., Huang, H., Sood, V. D., Wang, H., Zhao, X., Jenkins, M. H., Ji, Q., Wang, Y., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1744921 · Cited by 46
Cell-Death-Associated Molecular Patterns As Determinants of Cancer Immunogenicity
Ladoire, S., Hannani, D., Vétizou, M., Locher, C., Aymeric, L., Apétoh, L., Kepp, O., Kroemer, G., Ghiringhelli, F., & Zitvogel, L. (2013) · Antioxidants and Redox Signaling · doi:10.1089/ars.2012.5133 · Cited by 50
Modulation of APC Function and Anti-Tumor Immunity by Anti-Cancer Drugs
Martin, K., Schreiner, J., & Zippelius, A. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00501 · Cited by 46

Authors: Chiba, S., Baghdadi, M., Akiba, H., Yoshiyama, H., Kinoshita, I., Dosaka-Akita, H., Fujioka, Y., Ohba, Y., Gorman, J. V., Colgan, J. D., Hirashima, M., Uede, T., Takaoka, A., Yagita, H., & Jinushi, M.
Affiliations: Hokkaido University (JP)
Juntendo University (JP)
University of Iowa (US)
Kagawa University (JP)
Corresponding author: Jinushi, Masahisa
ORCID: Baghdadi, Muhammad
Akiba, Hisaya
Yoshiyama, Hironori
Kinoshita, Ichiro
Fujioka, Yoichiro
Ohba, Yusuke
Colgan, John D
Hirashima, Mitsuomi
Takaoka, Akinori
Venue: Nature Immunology
Publisher: Springer Science and Business Media LLC
Published: 2012-07-29
Volume: 13
Issue: 9
Pages: 832-842
ISSN: 1529-2908 (ISSN-L)
1529-2916
DOI: 10.1038/ni.2376
PMC: PMC3622453
OpenAlex: W2112400160
Cited by: 838
References: 50
Citations by year: 2026: 40 · 2025: 53 · 2024: 81 · 2023: 82 · 2022: 83 · 2021: 80 · 2020: 65 · 2019: 63 · 2018: 56 · 2017: 48 · 2016: 53 · 2015: 41 · 2014: 39 · 2013: 39 · 2012: 15
FWCI: 18.74
Type: journal article
Language: en
Open access: green
europepmc.org
Licence: www.springer.com/tdm (tdm)
Locations: Nature Immunology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Institutional Repositories DataBase (IRDB) (submittedVersion)
Hokkaido University Collection of Scholarly and Academic Papers (Hokkaido University) (submittedVersion)
Funders: Japan Society for the Promotion of Science (23590534, 23591132, 23501283, 22590360, 23390090, 22591098, 22240089, 23659196, 21390113)
National Institute of Allergy and Infectious Diseases (R01AI093737, R01AI067489)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords: TIM-3, HMGB1, tumor-associated dendritic cells, nucleic acid sensing, innate immunity, tumor microenvironment, Toll-like receptors, galectin-9, DNA vaccine, chemotherapy, antitumor immunity, alarmins
MeSH terms: Hepatitis A Virus Cellular Receptor 2, Animals, Dendritic Cells, Enzyme-Linked Immunosorbent Assay, Flow Cytometry, Humans, Immunity, Innate, Immunologic Surveillance, Mice, Inbred C57BL, Microscopy, Fluorescence, Neoplasms, Nucleic Acids, Receptors, Virus, Immunoblotting, Microscopy, Confocal, Reverse Transcriptase Polymerase Chain Reaction, HMGB1 Protein, Receptors, Pattern Recognition, Mice, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks